ChronoScale Holdings Corporatio (CHRN) Stock Analysis

Ekso Bionics generated most of its revenue from Enterprise Health sales of the EksoNR and Ekso Indego Therapy rehabilitation exoskeletons to inpatient rehabilitation facilities, while its Personal Health segment sold the Ekso Indego Personal device to individuals, aided by an April 2024 CMS Medicare reimbursement determination of approximately $91,000 per device. As of December 31, 2025, an estimated 309,000 people were living with spinal cord injury in the U.S. The company had signed distribution agreements with National Seating & Mobility, Bionic Prosthetics & Orthotics Group, and Ottobock Patient Care to expand reimbursement volume.

In its Enterprise Health market, Ekso Bionics sold EksoNR and Ekso Indego Therapy devices to rehabilitation facilities - primarily larger integrated delivery networks - either as outright capital sales or through 12-to-36-month subscription arrangements financed by third-party partners, layering on the EksoCare extended-warranty and clinical-support program and multi-year training packages; sales cycles ran eight to twelve months for a facility's first device. The company also sold the Ekso EVO upper-body exoskeleton to industrial customers in aerospace, automotive, and manufacturing to reduce worker fatigue and injury. In Personal Health, Ekso Indego Personal reached individual users with spinal cord injuries through Durable Medical Equipment suppliers who pursued Medicare, Medicaid, VA, or workers'-compensation reimbursement on the patient's behalf, plus self-pay and private-insurance channels; the VA, with 25 SCI centers, represented the largest single network of SCI care Ekso Bionics served. The company intended to shift a significant share of manufacturing to third-party contractors to reduce costs, though it had no long-term manufacturing or supply agreements in place.